VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
VTAE was delisted on the 24th of October, 2016.
53 hedge funds and large institutions have $193M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2015 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 14 closing their positions.
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
40% more capital invested
Capital invested by funds: $138M → $193M (+$54.7M)
2% more funds holding
Funds holding: 52 → 53 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.49M |
| 2 |
Millennium Management
New York
|
+$7.97M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.36M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.24M |
| 5 |
PA
Perceptive Advisors
New York
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WT
Wellcome Trust
London,
United Kingdom
|
-$4.95M |
| 2 |
Goldman Sachs
New York
|
-$1.9M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$807K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$609K |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$414K |
VTAE Hedge Fund Activity: Q2 2015 in Review
53 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q2 2015, worth a combined $193M — up 40% from $138M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new VTAE positions and 14 closed out — a net gain of 1 holder — while 23 added to existing stakes and 8 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $8.49M. The largest seller was Wellcome Trust, exiting entirely with an estimated $4.95M sold.
- 53 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q2 2015, up from 52 in Q1 2015.
- Funds reported $193M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q2 2015, up 40% quarter-over-quarter.
- 15 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q2 2015 and 14 closed out, a net change of +1 holder.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q2 2015 was Adage Capital Partners, an estimated $8.49M added.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q2 2015 was Wellcome Trust, an estimated $4.95M sold.
Based on aggregated 13F filings for Q2 2015.